In this context, the use of (sulfo)coumarin cores as CAIs represents the most used strategy to selectively target the cancer-associated hCAs IX and XII, avoiding inhibition of the cytosolic and off-target hCAs I and II. The gene discussed is CYP24A1; the disease is cancer.